<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00896181</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-15411</org_study_id>
    <secondary_id>NCI-2009-01162</secondary_id>
    <secondary_id>CDR0000671087</secondary_id>
    <secondary_id>8209</secondary_id>
    <secondary_id>ENT0025</secondary_id>
    <nct_id>NCT00896181</nct_id>
    <nct_alias>NCT00841997</nct_alias>
  </id_info>
  <brief_title>Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)</brief_title>
  <official_title>A Phase 2 Study of Sequential and Concurrent Chemoradiation for Patients With Advanced Nasopharyngeal Carcinoma (NPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 2 trial is studying whether giving a combination of docetaxel, cisplatin, and&#xD;
      fluorouracil chemotherapy followed by the combination of cisplatin with radiation therapy&#xD;
      works in treating patients with advanced nasopharyngeal cancer. Drugs used in chemotherapy,&#xD;
      such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of&#xD;
      tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy&#xD;
      uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a&#xD;
      high dose of radiation directly to the tumor may kill more tumor cells and cause less damage&#xD;
      to normal tissue. Giving combination chemotherapy together with radiation therapy may kill&#xD;
      more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      • To establish the progression free survival rate at 2 years, using RECIST criteria, to&#xD;
      induction treatment with docetaxel, cisplatin, and fluorouracil (TPF) followed by&#xD;
      chemoradiotherapy of locoregionally advanced nasopharyngeal carcinoma (NPC)&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      • To evaluate complete response rates, safety and feasibility of TPF followed by&#xD;
      chemoradiation in patients with NPC&#xD;
&#xD;
      OUTLINE: This is a single site study.&#xD;
&#xD;
      INDUCTION THERAPY: Patients receive docetaxel intravenously (IV) over 60 minutes on Day 1;&#xD;
      cisplatin IV over 1 to 3 hours (or carboplatin IV over 30 minutes) on Day 1; and fluorouracil&#xD;
      IV continuously over 24 hours on Days 1 to 5. Each cycle is 21 days, with treatment&#xD;
      consisting of up to 3 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      CONCURRENT CHEMO-RADIOTHERAPY: Beginning within 3 to 6 weeks after initiating the last course&#xD;
      of induction chemotherapy, patients undergo 3-dimensional conformal or intensity-modulated&#xD;
      radiotherapy once daily for 6.5 to 7 weeks. Patients also receive cisplatin IV over 1 hour&#xD;
      (or carboplatin IV over 30 minutes) once weekly in weeks 1 to 6 in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      All study treatment is admininstered over the course of 21 weeks. After completion of study&#xD;
      treatment, patients are followed periodically for 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 10, 2008</start_date>
  <completion_date type="Actual">December 2020</completion_date>
  <primary_completion_date type="Actual">January 3, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Progression-free Survival (PFS) at 2 Years After Chemo-radiotherapy</measure>
    <time_frame>up to 29 months (ie, 24 months post-chemoradiation)</time_frame>
    <description>Progression-free survival (PFS) means to remain alive without disease progression. Progression is defined as either the appearance of one or more new cancer lesions, or a ≥ 20% increase in the sum of the longest diameters (LD) of target cancer lesions, compared the same measurement obtained at the start of treatment. This outcome reported as the number of patients remaining alive at 2 years following chemo-radiotherapy without disease progression, a number without dispersion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Progression-free Survival (PFS)</measure>
    <time_frame>up to 127 months (includes treatment period of up to 5 months)</time_frame>
    <description>Progression-free survival (PFS) means to remain alive without disease progression. Progression is defined as either the appearance of one or more new cancer lesions, or a ≥ 20% increase in the sum of the longest diameters (LD) of target cancer lesions, compared the same measurement obtained at the start of treatment. This outcome reported as the median duration of PFS in months since chemo-radiotherapy, with full range.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 127 months (includes treatment period of up to 5 months)</time_frame>
    <description>Overall survival (OS) was assessed as the duration of time that study participants remained alive after chemoradiotherapy. The outcome is reported as median OS (with full range).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events Resulting in Treatment Discontinuation</measure>
    <time_frame>8 months</time_frame>
    <description>Adverse events during treatment were assessed as whether they were definitely-, probably-, or possibly-related to protocol treatment (ie, adverse reaction). The outcome is reported as the number of participants who discontinued treatment due to an adverse reaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Response</measure>
    <time_frame>up to 29 months (ie, 24 months post-chemoradiation)</time_frame>
    <description>Participants who completed 1 cycle of docetaxel, cisplatin, and 5-fluorouracil (TPF) were evaluated for response. Response was assessed for lesions designated as target (TL) and non-target (NTL) as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). The outcome is reported as a number without dispersion.&#xD;
TL Criterion:&#xD;
CR: Disappearance of lesions&#xD;
PR: 30% decrease in the sum of the longest diameter (LD) of lesions&#xD;
PD: 20% increase in the sum of the LD of lesions, or any new lesion&#xD;
SD: Neither sufficient shrinkage for PR nor sufficient increase for PD&#xD;
NTL Criterion:&#xD;
CR: Disappearance of lesions and normalization of tumor marker level&#xD;
PR / SD: Persistence of one or more lesion(s) and/or maintenance of tumor marker level above the normal limits (includes &quot;incomplete response / PR).&#xD;
PD: Appearance of one or more new lesions and/or unequivocal progression of existing lesions.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Stage II Lymphoepithelioma of the Nasopharynx</condition>
  <condition>Stage II Squamous Cell Carcinoma of the Nasopharynx</condition>
  <condition>Stage III Lymphoepithelioma of the Nasopharynx</condition>
  <condition>Stage III Squamous Cell Carcinoma of the Nasopharynx</condition>
  <condition>Stage IV Lymphoepithelioma of the Nasopharynx</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Nasopharynx</condition>
  <arm_group>
    <arm_group_label>Chemoradiation for Nasopharyngeal Carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INDUCTION THERAPY: Patients receive docetaxel intravenously (IV) over 60 minutes on Day 1; cisplatin IV over 1 to 3 hours (or carboplatin IV over 30 minutes) on Day 1; and fluorouracil IV continuously over 24 hours on Days 1 to 5. Each cycle is 21 days, with treatment consisting of up to 3 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
CONCURRENT CHEMO-RADIOTHERAPY: Beginning within 3 to 6 weeks after initiating the last course of induction chemotherapy, patients undergo 3-dimensional conformal or intensity-modulated radiotherapy once daily for 6.5 to 7 weeks. Patients also receive cisplatin IV over 1 hour (or carboplatin IV over 30 minutes) once weekly in weeks 1 to 6 in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Chemoradiation for Nasopharyngeal Carcinoma</arm_group_label>
    <other_name>RP 56976</other_name>
    <other_name>Taxotere</other_name>
    <other_name>TXT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Chemoradiation for Nasopharyngeal Carcinoma</arm_group_label>
    <other_name>CACP</other_name>
    <other_name>CDDP</other_name>
    <other_name>CPDD</other_name>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Chemoradiation for Nasopharyngeal Carcinoma</arm_group_label>
    <other_name>Carboplat</other_name>
    <other_name>CBDCA</other_name>
    <other_name>JM-8</other_name>
    <other_name>Paraplat</other_name>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Chemoradiation for Nasopharyngeal Carcinoma</arm_group_label>
    <other_name>5-fluorouracil</other_name>
    <other_name>5-Fluracil</other_name>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3-dimensional conformal radiation therapy</intervention_name>
    <description>Undergo 3-dimensional conformal or intensity-modulated radiotherapy</description>
    <arm_group_label>Chemoradiation for Nasopharyngeal Carcinoma</arm_group_label>
    <other_name>3D conformal radiation therapy</other_name>
    <other_name>3D-CRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation therapy</intervention_name>
    <description>Undergo 3-dimensional conformal or intensity-modulated radiotherapy</description>
    <arm_group_label>Chemoradiation for Nasopharyngeal Carcinoma</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          -  Histologically- or cytologically-confirmed nasopharyngeal carcinoma meeting the&#xD;
             following criteria:&#xD;
&#xD;
               -  WHO type I, II, or III&#xD;
&#xD;
               -  Stage II to IVB disease (minimally T2a, N0, M0 or any T any, N1, M0)&#xD;
&#xD;
               -  Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1&#xD;
                  dimension as ≥ 20 mm by conventional techniques or as ≥ 10 mm by spiral CT scan&#xD;
&#xD;
               -  Prior diagnostic surgery(s) at the primary site or neck allowed provided there is&#xD;
                  still measurable disease present&#xD;
&#xD;
               -  Without known brain metastases&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) ≤ 2.5 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL or creatinine clearance ≥ 55 mL/min (NOTE: * Patients with&#xD;
             creatinine &gt; grade 1 but &lt; grade 3, hearing loss ≥ grade 2, and peripheral neuropathy&#xD;
             ≥ grade 2 are eligible provided they receive carboplatin in place of cisplatin&#xD;
             throughout study treatment)&#xD;
&#xD;
          -  Hearing loss &lt; grade 2. Hearing loss grade 2 or greater attributable to tumor&#xD;
             obstruction, when the bone conduction in the audiogram is consistent with less than&#xD;
             grade 2, is permissible for cisplatin. Hearing loss will be evaluated by hearing in&#xD;
             the best ear. If hearing loss is grade 2, patients are still eligible but should&#xD;
             receive carboplatin throughout the protocol instead of cisplatin.&#xD;
&#xD;
          -  Peripheral motor/sensory neuropathy &lt; grade 2. If peripheral neuropathy is grade 2,&#xD;
             patients are still eligible but should receive carboplatin throughout the protocol&#xD;
             instead of cisplatin.&#xD;
&#xD;
          -  Fertile patients must use effective contraception prior to and during study treatment&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, any of the following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Psychiatric illness or social situations that preclude compliance with study&#xD;
                  requirements&#xD;
&#xD;
               -  Clinically-significant cardiovascular disease&#xD;
&#xD;
               -  Cerebrovascular accident within the past 6 months&#xD;
&#xD;
               -  Myocardial infarction or unstable angina within the past 6 months&#xD;
&#xD;
               -  New York Heart Association (NYHA) class II to IV congestive heart failure&#xD;
&#xD;
               -  Serious and inadequately controlled cardiac arrhythmia&#xD;
&#xD;
               -  Significant vascular disease (eg, aortic aneurysm, history of aortic dissection)&#xD;
&#xD;
               -  Clinically-significant peripheral vascular disease&#xD;
&#xD;
          -  History of allergic reaction attributed to compounds of similar chemical or biologic&#xD;
             composition to docetaxel, cisplatin, carboplatin, fluorouracil, bevacizumab, or other&#xD;
             agents used in this study&#xD;
&#xD;
          -  Known brain metastases&#xD;
&#xD;
          -  Concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  Prior chemotherapy or radiotherapy for nasopharyngeal carcinoma&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Colevas</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University Hospitals and Clinics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Hospitals and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 7, 2009</study_first_submitted>
  <study_first_submitted_qc>May 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2009</study_first_posted>
  <results_first_submitted>February 3, 2021</results_first_submitted>
  <results_first_submitted_qc>March 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 6, 2021</results_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>A. Dimitrios Colevas</investigator_full_name>
    <investigator_title>Professor of Medicine (Oncology)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 5, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT00896181/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Chemoradiation for Nasopharyngeal Carcinoma</title>
          <description>Induction therapy as described, consisting of docetaxel, cisplatin, and fluorouracil Concurrent chemo-radiotherapy as described, 3-dimensional radiotherapy once daily for 6.5 to 7 weeks, with cisplatin weekly.&#xD;
The total treatment course is up to 21 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chemoradiation for Nasopharyngeal Carcinoma</title>
          <description>Induction therapy as described, consisting of docetaxel, cisplatin, and fluorouracil Concurrent chemo-radiotherapy as described, 3-dimensional radiotherapy once daily for 6.5 to 7 weeks, with cisplatin weekly.&#xD;
The total treatment course is up to 21 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.3" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Progression-free Survival (PFS) at 2 Years After Chemo-radiotherapy</title>
        <description>Progression-free survival (PFS) means to remain alive without disease progression. Progression is defined as either the appearance of one or more new cancer lesions, or a ≥ 20% increase in the sum of the longest diameters (LD) of target cancer lesions, compared the same measurement obtained at the start of treatment. This outcome reported as the number of patients remaining alive at 2 years following chemo-radiotherapy without disease progression, a number without dispersion.</description>
        <time_frame>up to 29 months (ie, 24 months post-chemoradiation)</time_frame>
        <population>The outcome results are reported by baseline strata, ie, M0 (non-metastatic lesions) and M1 (metastatic lesions).</population>
        <group_list>
          <group group_id="O1">
            <title>Chemoradiation for Nasopharyngeal Carcinoma</title>
            <description>Induction therapy as described, consisting of docetaxel, cisplatin, and fluorouracil Concurrent chemo-radiotherapy as described, 3-dimensional radiotherapy once daily for 6.5 to 7 weeks, with cisplatin weekly.&#xD;
The total treatment course is up to 21 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Progression-free Survival (PFS) at 2 Years After Chemo-radiotherapy</title>
          <description>Progression-free survival (PFS) means to remain alive without disease progression. Progression is defined as either the appearance of one or more new cancer lesions, or a ≥ 20% increase in the sum of the longest diameters (LD) of target cancer lesions, compared the same measurement obtained at the start of treatment. This outcome reported as the number of patients remaining alive at 2 years following chemo-radiotherapy without disease progression, a number without dispersion.</description>
          <population>The outcome results are reported by baseline strata, ie, M0 (non-metastatic lesions) and M1 (metastatic lesions).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M0 (non-metastatic lesion)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M1 (metastatic lesion)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Progression-free Survival (PFS)</title>
        <description>Progression-free survival (PFS) means to remain alive without disease progression. Progression is defined as either the appearance of one or more new cancer lesions, or a ≥ 20% increase in the sum of the longest diameters (LD) of target cancer lesions, compared the same measurement obtained at the start of treatment. This outcome reported as the median duration of PFS in months since chemo-radiotherapy, with full range.</description>
        <time_frame>up to 127 months (includes treatment period of up to 5 months)</time_frame>
        <population>The outcome results are reported by baseline strata, ie, M0 (non-metastatic lesions) and M1 (metastatic lesions).</population>
        <group_list>
          <group group_id="O1">
            <title>Chemoradiation for Nasopharyngeal Carcinoma</title>
            <description>Induction therapy as described, consisting of docetaxel, cisplatin, and fluorouracil Concurrent chemo-radiotherapy as described, 3-dimensional radiotherapy once daily for 6.5 to 7 weeks, with cisplatin weekly.&#xD;
The total treatment course is up to 21 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression-free Survival (PFS)</title>
          <description>Progression-free survival (PFS) means to remain alive without disease progression. Progression is defined as either the appearance of one or more new cancer lesions, or a ≥ 20% increase in the sum of the longest diameters (LD) of target cancer lesions, compared the same measurement obtained at the start of treatment. This outcome reported as the median duration of PFS in months since chemo-radiotherapy, with full range.</description>
          <population>The outcome results are reported by baseline strata, ie, M0 (non-metastatic lesions) and M1 (metastatic lesions).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M0 (non-metastatic lesion)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="15" upper_limit="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M1 (metastatic lesion)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="12" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival (OS) was assessed as the duration of time that study participants remained alive after chemoradiotherapy. The outcome is reported as median OS (with full range).</description>
        <time_frame>up to 127 months (includes treatment period of up to 5 months)</time_frame>
        <population>The outcome results are reported by baseline strata, ie, M0 (non-metastatic lesions) and M1 (metastatic lesions). The per-protocol duration of treatment on study was 5 months, and the outcome is reported as OS (with full range) from that time.</population>
        <group_list>
          <group group_id="O1">
            <title>Chemoradiation for Nasopharyngeal Carcinoma</title>
            <description>Induction therapy as described, consisting of docetaxel, cisplatin, and fluorouracil Concurrent chemo-radiotherapy as described, 3-dimensional radiotherapy once daily for 6.5 to 7 weeks, with cisplatin weekly.&#xD;
The total treatment course is up to 21 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival (OS) was assessed as the duration of time that study participants remained alive after chemoradiotherapy. The outcome is reported as median OS (with full range).</description>
          <population>The outcome results are reported by baseline strata, ie, M0 (non-metastatic lesions) and M1 (metastatic lesions). The per-protocol duration of treatment on study was 5 months, and the outcome is reported as OS (with full range) from that time.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M0 (non-metastatic lesion)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="26" upper_limit="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M1 (metastatic lesion)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="18" upper_limit="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events Resulting in Treatment Discontinuation</title>
        <description>Adverse events during treatment were assessed as whether they were definitely-, probably-, or possibly-related to protocol treatment (ie, adverse reaction). The outcome is reported as the number of participants who discontinued treatment due to an adverse reaction.</description>
        <time_frame>8 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chemoradiation for Nasopharyngeal Carcinoma</title>
            <description>Induction therapy as described, consisting of docetaxel, cisplatin, and fluorouracil Concurrent chemo-radiotherapy as described, 3-dimensional radiotherapy once daily for 6.5 to 7 weeks, with cisplatin weekly.&#xD;
The total treatment course is up to 21 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events Resulting in Treatment Discontinuation</title>
          <description>Adverse events during treatment were assessed as whether they were definitely-, probably-, or possibly-related to protocol treatment (ie, adverse reaction). The outcome is reported as the number of participants who discontinued treatment due to an adverse reaction.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Response</title>
        <description>Participants who completed 1 cycle of docetaxel, cisplatin, and 5-fluorouracil (TPF) were evaluated for response. Response was assessed for lesions designated as target (TL) and non-target (NTL) as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). The outcome is reported as a number without dispersion.&#xD;
TL Criterion:&#xD;
CR: Disappearance of lesions&#xD;
PR: 30% decrease in the sum of the longest diameter (LD) of lesions&#xD;
PD: 20% increase in the sum of the LD of lesions, or any new lesion&#xD;
SD: Neither sufficient shrinkage for PR nor sufficient increase for PD&#xD;
NTL Criterion:&#xD;
CR: Disappearance of lesions and normalization of tumor marker level&#xD;
PR / SD: Persistence of one or more lesion(s) and/or maintenance of tumor marker level above the normal limits (includes &quot;incomplete response / PR).&#xD;
PD: Appearance of one or more new lesions and/or unequivocal progression of existing lesions.</description>
        <time_frame>up to 29 months (ie, 24 months post-chemoradiation)</time_frame>
        <population>The outcome results are reported by baseline strata, ie, M0 (non-metastatic lesions) and M1 (metastatic lesions).</population>
        <group_list>
          <group group_id="O1">
            <title>Chemoradiation for Nasopharyngeal Carcinoma</title>
            <description>Induction therapy as described, consisting of docetaxel, cisplatin, and fluorouracil Concurrent chemo-radiotherapy as described, 3-dimensional radiotherapy once daily for 6.5 to 7 weeks, with cisplatin weekly.&#xD;
The total treatment course is up to 21 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Response</title>
          <description>Participants who completed 1 cycle of docetaxel, cisplatin, and 5-fluorouracil (TPF) were evaluated for response. Response was assessed for lesions designated as target (TL) and non-target (NTL) as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). The outcome is reported as a number without dispersion.&#xD;
TL Criterion:&#xD;
CR: Disappearance of lesions&#xD;
PR: 30% decrease in the sum of the longest diameter (LD) of lesions&#xD;
PD: 20% increase in the sum of the LD of lesions, or any new lesion&#xD;
SD: Neither sufficient shrinkage for PR nor sufficient increase for PD&#xD;
NTL Criterion:&#xD;
CR: Disappearance of lesions and normalization of tumor marker level&#xD;
PR / SD: Persistence of one or more lesion(s) and/or maintenance of tumor marker level above the normal limits (includes &quot;incomplete response / PR).&#xD;
PD: Appearance of one or more new lesions and/or unequivocal progression of existing lesions.</description>
          <population>The outcome results are reported by baseline strata, ie, M0 (non-metastatic lesions) and M1 (metastatic lesions).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR for M0 (non-metastatic lesion)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR for M0 (non-metastatic lesion)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SD for M0 (non-metastatic lesion)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PD for M0 (non-metastatic lesion)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CR for M1 (metastatic lesion)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR for M1 (metastatic lesion)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SD for M1 (metastatic lesion)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PD for M1 (metastatic lesion)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for up to 104 months and All-Cause Mortality was collected up to 127 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Chemoradiation for Nasopharyngeal Carcinoma</title>
          <description>Induction therapy as described, consisting of docetaxel, cisplatin, and fluorouracil Concurrent chemo-radiotherapy as described, 3-dimensional radiotherapy once daily for 6.5 to 7 weeks, with cisplatin weekly.&#xD;
The total treatment course is up to 21 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Gastric Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboemobolic event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="12" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="56" subjects_affected="11" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing Impaired</sub_title>
                <counts group_id="E1" events="26" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oral Mucositis</sub_title>
                <counts group_id="E1" events="96" subjects_affected="24" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Acid Reflux</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="7" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="8" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Oral Pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Salivary Duct Inflammation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Typhlitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Xerostomia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Salivary Duct Inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="27" subjects_affected="10" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, Coronavirus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Skin Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, Thrush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Otitis Externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Dermatitis radiation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Alanine Aminotransferace Increase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="114" subjects_affected="18" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" events="18" subjects_affected="7" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="8" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Creatinine Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="5" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="5" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pain in Extremities</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="32" subjects_affected="6" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Laryngeal Inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="11" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Palmar Plantar Syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, skin changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, skin problems</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. A. Dimitrios Colevas, Professor of Medicine (Oncology)</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-724-9707</phone>
      <email>colevas@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

